38 POSTER Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors
2006 ◽
Vol 4
(12)
◽
pp. 16
◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 14521-14521
2011 ◽
Vol 18
(4)
◽
pp. 1092-1100
◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 2530-2530
◽
2008 ◽
Vol 14
(7)
◽
pp. 2075-2081
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3016-3016
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 2530-2530
◽